Photo

jbarrett@bcg-usa.com

Julia Barrett

CV in Adobe

Contact

 

EXPERTISE

  • Clinical and regulatory consulting services to the biotechnology industry, pharmaceutical industry and academia.
  • Consultation regarding clinical and public health issues as they pertain to the development of new products and clinical trials
  • Providing clinical development plans for early phase biologics and drugs
  • Comprehensive FDA style review of PIND, IND, BLA, and NDA submissions
  • Design, preparation and implementation of Phase 1, 2, 3 and 4 clinical triala
  • Clinical protocol development
  • Assistance with GCP compliance
  • Comprehensive review of safety and efficacy data
  • Medical monitoring
  • Assistance with the conduct of clinical trials, including consent forms, case report forms, IRBs, DSMBs, selection of investigators, safety monitoring and reporting
  • Preparation for FDA meetings and advisory committees
  • CRO oversight for ongoing studies

EDUCATION:

M.S.   Public Health (MPH) George Washington University, Washington, DC (1992)
    Trinity College of Music, London, England, Non-Degree Program in Violin Performance
(1982-1983)
M.D.   Northwestern University School of Medicine, Chicago, IL (1987)
B.A.   Smith College, Northampton, MA; Biology cum laude (1982)

EXPERIENCE:
(Regulatory and Product Development Experience)

CURRENT
POSITION:
  Senior Clinical Consultant, Biologics Consulting Group, Inc.
Evergreen, CO.
Dec. 2004 to
present
  Provide clinical and regulatory consulting services to the biotechnology industry, pharmaceutical industry and academia. Five years of experience as a clinical reviewer at the FDA, in addition to my training in Internal Medicine and Public Health, enhances my ability to consult in a number of clinical and regulatory areas.
   
1998 - Nov. 2004   Affiliate, Biologics Consulting Group, L.L.C.
Evergreen, CO.
   
1998 - Dec. 2004   Clinical and Regulatory Consultant
Evergreen, CO
   
1999 - 2004  

SouthPark Internal Medicine
Littleton, CO

  • Practice of Internal Medicine
   
1998  

Women's Health Specialists
Denver, CO.

  • Practice of Internal Medicine
   
1997  

Part-time staff physician, National Naval Medical Center, Department of Medicine,
Bethesda, MD.

  • Precepted a Physical Diagnosis course for first year medical students
   
1992 - 1997  

Senior Clinical Reviewer, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Office of Vaccines Research and Review, Division of Vaccines and Related Products Applications, Clinical Trials Branch
Bethesda, MD.

IND Review:

  • Responsible for the comprehensive review of protocols for Phase 1, 2 and 3 clinical studies.
  • Assessed the rationale, safety and design of clinical studies submitted to over 80 INDs (Investigational New Drug Applications) for bacterial, viral (including HIV) and DNA vaccines, as well as several biological therapeutic products.
  • It was my recommendation which determined whether a study was allowed to proceed or placed on clinical hold.
  • Responsible for training new physicians who joined our Division.

PLA/BLA Review:

  • Responsible for the review of clinical data submitted in PLAs (Product License Applications) to support the licensure of new vaccines and other biological products.
  • Performed a complete review of all clinical data submitted and then formally presented my conclusions and recommendations at an FDA Advisory Committee.

Guidance to Industry:

  • Provided guidance regarding the overall clinical development of investigational products, including such topics as the type and quantity of preclinical data necessary to initiate Phase 1 studies, the need for dose-ranging studies, the choice of efficacy endpoints for pivotal Phase 3 trials, and the size of the safety database necessary for licensure.

Policy and Regulatory Document Development:

  • Participated in a variety of special FDA projects and committees ranging from combination pediatric vaccines to HIV vaccines to the inclusion of women in clinical trials.
  • Served on many FDA policy committees and participated in the writing and review of regulatory documents.
   
1993 - 1995  

Part-time staff physician, National Cancer Institute, Division of Cancer Treatment, Medicine Branch, Retroviral Diseases Section, HIV Clinic.
Bethesda, MD.

  • Assisted in conducting Phase 1 and 2 studies of HIV therapeutics.
   
1990 - 1992  

Fellowship in General Internal Medicine, George Washington University, Department of Health Care Sciences.
Washington, DC

   
1987 - 1990   Internship and Residency in Internal Medicine, University of Minnesota
Minneapolis, MN

AWARDS:
1997   FDA Commendable Service Award for superior performance in the clinical review of vaccine and therapeutic products.

CERTIFICATIONS:
2000   American Board of Internal Medicine Recertification
1990   American Board of Internal Medicine
1988   National Board of Medical Examiners

MEDICAL LICENSURE:
1997-present   Colorado (inactive status since 2005)
1991 - 1997   Maryland
1990 - 1992   District of Columbia
1989 - 1990   Minnesota

COMMITTEE MEMBERSHIP:

2004-present  

Member of NIH review committee for the Vaccine Treatment and Evaluation Units (VTEUs for HIV vaccine and treatment studies)

1997   Member of the FDA Pregnancy Registry Working Group that evaluated product labeling pertaining to the use of drugs and biologics during pregnancy.
1994-1997
  Reviewer of documents from Second International Conference on Harmonization (ICH).
1994-1997   FDA representative on the AIDS Clinical Trials Group (ACTG) HIV Specific Immunity Subcommittee of the Pediatric Vaccine Committee.
1994-1995   Member of the FDA Information Standards Steering Committee's Clinical Laboratory Data Working Group.
1994   Member of an FDA committee that discussed issues and policy regarding the inclusion of women in clinical trials.
1993-1994   Member of an FDA committee that produced the document entitled "Evaluation of Combination Vaccines: Production, Testing and Clinical Study".

PRESENTATIONS & CONFERENCES:

Aug 2008  

Presentation at CHI’s conference “Clinical Risk Management and Safety for Vaccines” entitled “Clinical and Regulatory Considerations for the Development of Vaccines.”  Boston, MA.

Mar 2007   Presentation at the World Vaccine Congress 2007 entitled “Clinical Development Considerations for Vaccines.”  Washington, DC.
Oct 2005   Presentation at bioLOGIC 2005 entitled "Clinical Development of Biodefense Vaccines." Boston, MA.
1999-present   Multiple presentations to clients regarding Good Clinical Practices (GCP)
July 1999   Presentation entitled "Establishing and Using Serological Correlates of Protection" and "Preparation and Use of Documents to Support Clinical Trials." Pentagon City, VA.
May 1997   Presentation entitled "Adverse Event Reporting: What, When and How? A Vaccine Perspective." Walter Reed Army Medical Center. Silver Spring, MD.
July 1996   Presentation before the FDA's Vaccines and Related Biological Products Advisory Committee (CBER) in which I discussed clinical data submitted to support an acellular DTP vaccine. This new pediatric vaccine was approved by FDA. Rockville, MD.
Apr. 1996   Presentation on the topic of IND Clinical Review at a conference entitled "Regulatory Issues Related to Novel Product and Process Technologies." This conference was sponsored by the Pacific Region biotechnology industry in conjunction with the Food and Drug Administration. Irvine, CA.
Nov. 1995   Co-chair at a conference entitled "Improving the Performance of Influenza and Pneumococcal Vaccines in Adults." This session addressed immunogenicity and safety issues in influenza and pneumococcal vaccine development. Washington, DC.
May 1993   Presentation before the FDA's Antiviral Drugs Advisory Committee (CDER) in which I discussed clinical data submitted to support the use of intravenous Immune Globulin (IVIG) to prevent bacterial infections in HIV-infected children. This new indication for IVIG was approved by the FDA. Rockville, MD.

RESEARCH AND PUBLICATIONS:

2008
  AA McCormick, S Reddy, SF Reinl, TI Cameron, DK Czerwinski, F Voljdani, KM Hanley, SJ Garger, EL White, J Novak, J Barrett, RB Holtz, D Tuse, R Levy (2008). Plant-produced idiotype vaccines for the treatment of non-Hodgkin’s lymphoma: Safety and immunogenicity in a phase I clinical study. PNAS: 105 (29): 10131-10136.
1997
  Book chapter entitled "The Biological IND" Biologics Development: A Regulatory Overview, Authors: Jeanne Novak, Julia Barrett, Loris McVittie and Donna Chandler, Editor: Mark Mathieu, Published by Parexel International Corporation
1997
  Book chapter entitled "The IND for Biological Products" Global Biotechnology Product Registration: E.U., U.S. and Japan, Authors: Jeanne Novak, Julia Barrett, Loris McVittie, Donna Chandler and Mark Mathieu, Editor: Mark Mathieu, Published by Parexel International Corporation
1991 - 1992
  National Cancer Institute, Bethesda, MD, Division of Cancer Prevention and Control, Early Detection and Community Oncology Program, Epidemiological study examining rural-urban differences in the stage at diagnosis of breast and cervical carcinoma
   
Page Updated: August 13, 2008

 

Copyright © 2007  Biologics Consulting Group, Inc. - All Rights Reserved